Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Anti-Inflammatory Biologics Market Size And Revenue Outlook Through 2030
The anti-inflammatory biologics market size has demonstrated significant growth over recent years. It is projected to increase from $118.02 billion in 2025 to $128.84 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. This historical expansion can be attributed to various factors, including the increasing prevalence of conditions such as rheumatoid arthritis and psoriasis, the strengthening of hospital and clinic infrastructure, and greater investment in immunology research. Additionally, the initial limited availability of biologics and a previous reliance on traditional anti-inflammatory drugs also contributed to this growth.
The anti-inflammatory biologics market size is projected to experience substantial growth in the upcoming years. It is expected to expand to $180.93 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 8.9%. This anticipated growth can be attributed to several factors, including the advancement of next-generation cytokine inhibitors, the broadening of home care and self-administration choices, an increase in regulatory approvals coupled with swifter clinical trial processes, escalating investment in precision medicine and biologics research and development, and the expansion of partnerships between pharmaceutical and biotechnology enterprises. Significant trends for the forecast period comprise the increasing utilization of targeted biologics for persistent inflammatory conditions, the wider adoption of subcutaneous and injectable drug delivery methods, a surge in clinical trials and research dedicated to innovative anti-inflammatory biologics, an intensified focus on customized treatment approaches, and enhanced awareness and availability of biologics in developing markets.
Get A Free Sample Report With In-Depth Market Insights:
Anti-Inflammatory Biologics Market Growth Backed By Core Demand Fundamentals
The increasing incidence of arthritis is projected to drive the expansion of the anti-inflammatory biologics market in the foreseeable future. Arthritis is defined as the inflammation or swelling in one or more joints, leading to pain, stiffness, and reduced movement, often worsening with advancing age. The heightened prevalence of arthritis primarily stems from rising obesity rates, as excess body weight places additional stress on joints, which in turn causes inflammation and joint degeneration. Anti-inflammatory biologics prove beneficial for arthritis by targeting specific components of the immune system to decrease inflammation, slow down joint damage, relieve symptoms, and enhance physical function and quality of life for individuals with moderate to severe arthritis. For example, in January 2024, the Office for Health Improvement and Disparities, a UK-based government department, reported that in 2023, 18.4% of people aged 16 and over indicated they had a long-term MSK condition, an increase from 17.6% in 2022. Thus, the growing prevalence of arthritis is fueling the growth of the anti-inflammatory biologics market.
Anti-Inflammatory Biologics Market Segmentation And Category Overview
The anti-inflammatory biologics market covered in this report is segmented –
1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes
2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous
3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes
Subsegments:
1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol
2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors
3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab
4) By T-Cell Inhibitors: Abatacept, Alefacept
5) By Other Drug Classes: Janus Kinase Inhibitors, Anti-IgE And Other Biologics
Anti-Inflammatory Biologics Market Growth Trends Reshaping The Competitive Landscape
Leading firms within the anti-inflammatory biologics sector are concentrating on creating novel treatments, including interleukin-6 (IL-6) receptor antagonists, to address chronic inflammatory conditions more precisely and with fewer adverse reactions. Interleukin-6 (IL-6) receptor antagonists are a class of biologic medications designed to obstruct the IL-6 receptor, thereby diminishing inflammation and immune activity in illnesses like rheumatoid arthritis. For example, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, obtained clearance from the US Food and Drug Administration (FDA) for Kevzara. This marks Kevzara as the initial and sole biologic therapy for individuals suffering from polymyalgia rheumatica (PMR) who exhibit an insufficient response to corticosteroids. Kevzara functions as a fully human monoclonal antibody, inhibiting the IL-6 receptor to aid in lessening the inflammation associated with PMR, a condition predominantly affecting older adults with symptoms of muscle pain and stiffness. In contrast to conventional steroids, which pose long-term risks like osteoporosis and diabetes, Kevzara offers a more focused, steroid-reducing method, promoting better patient results and heightened long-term safety.
Anti-Inflammatory Biologics Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc, UCB S.A
View The Full Anti-Inflammatory Biologics Market Report:
Anti-Inflammatory Biologics Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the anti-inflammatory biologics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model